This is a study to compare two formulations of Clozapine in Schizophrenic Patients
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2016/07/007083
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 56
•Patients of either sex, aged 18 to 55 years (both inclusive) having clinical diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria (DSM-V TR)
•Patients with body mass index between 18 and 25 kg/m2
•Patients who are appropriate candidates for Clozapine therapy (as stated in ZIPROC-100 and LEPONEX® package inserts) and have been taking a stable dose of Clozapine 100 mg twice daily for at least three months before enrolment in the study
•Patients who are healthy as determined by physical examination, medical history, and no significant abnormality in any of the laboratory parameters, including electrocardiogram and Chest x-ray
•Ability to comprehend the full nature and purpose of the study, including possible risks and adverse events (AEs); ability to co-operate with the investigator and study team and to comply with the requirements of the entire study
•Patients/legally acceptable representative has given written consent after being advised of the nature and risks of the study
•Patients must have adequate hematologic reserve:
Hemoglobin (Hb) >= 11 gm/dL
White blood cells (WBC) >= 4000 /mm3 or /μL
Platelets >= 100,000 mm3 or /μL
Absolute neutrophil count (ANC) >= 2000 /mm3 or /μL
•Adequate and stable hepatic function at screening as defined by:
Bilirubin <= 1.5 Ã? ULN (upper limit of normal)
Aspartate aminotransferase/alanine aminotransferase (AST/
ALT) <= 1.5 Ã? ULN
Total triglycerides <= 1.5 Ã? ULN
Total cholesterol <= 1.5 Ã? ULN
•Adequate renal function at screening as defined by:
Creatinine <= ULN for the clinical laboratory
Serum potassium <= ULN
Serum magnesium <= ULN
•Female patients of childbearing potential must have a negative urine pregnancy test at screening and check-in
•History of suicidal tendencies (e.g. suicidal attempts) within the past 3 months prior to screening or immediate risk of harm to self or other at the time of screening, as judged by the investigator
•Elderly patients with diagnosed dementia related psychosis
•Patients with medical or surgical condition that might interfere with the absorption, metabolism, or excretion of Clozapine or other study medications
•Patients with history of granulocytopenia or myeloproliferative disorder, either drug-induced or idiopathic
•Patients with history of clinically significant cardiovascular, renal, hepatic, respiratory, endocrine (except noninsulin-dependent diabetes mellitus), or gastrointestinal disease
•Patientâ??s positive for HIV, HBs Ag or HCV
•Patients with history of epilepsy or seizures or are comatose or experiencing severe central nervous system depression
•Patients who are unable to communicate with the investigator and study team
•Patients with a history of allergic reactions to Clozapine or chemically related psychotropic drugs
•Patients having concurrent primary psychiatric or neurological diagnosis, including organic mental disorder (DSM-V criteria), mental retardation, severe tardive dyskinesia, or idiopathic Parkinsonâ??s disease
•Patients who had undergone electroconvulsive therapy within the past 1 month
•Patients have demonstrated clinically significant homicidal behaviour within the past 12 months
•Patients have received any investigational drug within the past 90 days
•Patients having a history of narrow-angle glaucoma
•Patients requiring treatment with drugs that are known to interact with Clozapine (e.g., agents having a well-known potential to suppress bone- marrow functioning, drugs that are highly protein-bound, cimetidine, or phenytoin). Clozapine may also potentiate the effects of antihypertensive and anticholinergics; therefore, caution should be taken if patients receiving these drugs are enrolled in the study
•Patients with known history of phenylketonuria
•Significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 30 mm Hg or more and / or a drop in diastolic blood pressure of 20 mm Hg or more on standing)
•Concurrent use of antihypertensive medication or any medication that might pre-dispose to orthostatic hypotension
• Positive tests for drug or alcohol abuse at screening and before check-in
•A history of alcohol or drug dependence by DSM-V criteria during the 6-month period immediately prior to study entry
•History of multiple syncopal episodes
•Patients who smoke more than 10 cigarettes / day or unable to abstain from smoking during the study
•Expected changes in concomitant medication during the period of study
Study & Design
- Study Type
- BA/BE
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method â?¢AUC0-tau ss: Area under the plasma concentration â?? time curve over the steady state dosing interval <br/ ><br> <br/ ><br>â?¢Cmax ss: Maximum concentration over the steady state dosing interval <br/ ><br>Timepoint: On Day 10 and Day 20
- Secondary Outcome Measures
Name Time Method â?¢Cmin ss: Minimum concentration over the steady state dosing interval <br/ ><br>â?¢Cavg ss: Average concentration over the steady state dosing interval <br/ ><br>â?¢Tmax ss: Time of maximum measured plasma concentration over the steady state dosing interval <br/ ><br>â?¢Percentage fluctuation: [100 Ã? (Cmax ss - Cmin ss)/Cavg ss] <br/ ><br>â?¢Swing [Cmax ss â?? C min ss/Cmin ss] Ã? 100 <br/ ><br>â?¢Cpd (pre-dose concentration)-Pre-dose concentrations determined before a dose at steady stateTimepoint: Cmin ss, Cavg ss, Tmax ss, Percentage fluctuation, Swing on Day 10 and Day 20 <br/ ><br> <br/ ><br>Cpd (pre-dose concentration) on Day 7 to Day 10; Day 17 to Day 20